Shares of PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) traded up 8.9% during mid-day trading on Friday . The company traded as high as $0.50 and last traded at $0.4162. 3,377,877 shares changed hands during mid-day trading, an increase of 38,150% from the average daily volume of 8,831 shares. The stock had previously closed at $0.3823.
PharmaCyte Biotech Stock Performance
The firm’s fifty day moving average price is $0.56 and its 200 day moving average price is $0.67.
PharmaCyte Biotech Company Profile
PharmaCyte Biotech is a clinical‐stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose‐based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.
In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.
See Also
- Five stocks we like better than PharmaCyte Biotech
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
